Drug Trial Radar · NCT06680752
Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS
Last checked: Nov 19, 2026Latest source record: Dec 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
49
Planned (sponsor's estimate)
Start
May 20, 2025
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- ARCE Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Nov 8, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase I/2, interventional, open-label, multicenter study to assess the safety and efficacy of ARD103 in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Conditions
- Acute Myeloid Leukemia, in Relapse
- Acute Myeloid Leukemia Refractory
- MDS (Myelodysplastic Syndrome)
Interventions
ARD103Biological
ARD103 autologous CAR-T cell therapy targeting CLL-1, single iv. infusion
CyclophosphamideDrug
iv administration for lymphodepletion
FludarabineDrug
iv administration for lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 28 days post ARD103 infusion
- To determine the RP2D of ARD103Time frame: 28 days post ARD103 infusion
- To evaluate overall response rate (ORR)Time frame: Up to 24 months
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Novant Health Cancer Institute
Charlotte, North Carolina · Recruiting
Novant Health Cancer Institute
Winston-Salem, North Carolina · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.